



Published in final edited form as:

Cancer Causes Control. 2016 February ; 27(2): 183–198. doi:10.1007/s10552-015-0696-z.

Breast cancer risk factor associations differ for pure versus invasive carcinoma with an *in situ* component in case-control and case-case analyses

Melanie Rusczyk¹¹, Gary Zirpoli¹, Shicha Kumar², Elisa V. Bandera^{3,4}, Dana H. Bovbjerg⁵, Lina Jandorf⁶, Thaer Khoury⁷, Helena Hwang⁸, Gregory Ciupak¹, Karen Pawlish⁹, Pepper Schedin¹⁰, Patricia Masso-Welch¹¹, Christine B. Ambrosone¹, and Chi-Chen Hong^{1,*}

¹Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm & Carlton Sts., Buffalo, NY 14263

²Department of Surgical Oncology, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263

³Population Science/Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, 195 Little Albany St, New Brunswick, NJ 08903

⁴Department of Epidemiology, Rutgers School of Public Health, 683 Hoes Ln W, Piscataway, NJ 08854

⁵Department of Psychiatry, University of Pittsburgh Cancer Institute, 5150 Centre Ave, Pittsburgh, PA 15232

⁶Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1428 Madison Ave, New York, NY 10029

⁷Department of Pathology, University of Texas, Southwestern Medical Center, 5325 Harry Hines Blvd, Dallas, TX 75390

* To whom correspondence should be addressed. Roswell Park Cancer Institute, Carlton House, Elm & Carlton Sts., Buffalo, NY 14263, Tel: +1 716 845-7785; Fax: +1 716 845-8125, chi-chen.hong@roswellpark.org.

mur@buffalo.edu

gary.zirpoli@roswellpark.org

shicha.kumar@roswellpark.org

banderel@cinj.rutgers.edu

bovbjergdh@upmc.edu

lina.jandorf@mssn.edu

thaer.khoury@roswellpark.org

helena.hwang@utsouthwestern.edu

gregory.ciupak@roswellpark.org

karen.pawlish@doh.state.nj.us

schedin@ohsu.edu

pmwelch@buffalo.edu

christine.ambrosone@roswellpark.org

Compliance with ethical standards

WCHS protocols for agreement to participate and informed consent were approved by the Institutional Review Boards at Roswell Park Cancer Institute (RPCI), Rutgers Cancer Institute of New Jersey (CINJ), Icahn School of Medicine at Mount Sinai School (ISMMSS; formerly the Mount Sinai School of Medicine), and the participating hospitals in NYC in compliance with the Declaration of Helsinki.

Informed consent: Informed consent was obtained from all individual participants included in the study.

Conflict of Interest: The authors declare that they have no competing interests.

⁸Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263

⁹New Jersey State Cancer Registry, New Jersey Department of Health, 140 East Front St, Trenton, NJ 08625

¹⁰Department of Cell, Developmental and Cancer Biology, Oregon Health Sciences University, 3181 SW Sam Jackson Pkwy, Portland, OR 97239

¹¹Department of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, 12 Capen Hall, Buffalo, NY 14214, USA

Abstract

Purpose—Invasive ductal carcinoma (IDC) is diagnosed with or without a ductal carcinoma in situ (DCIS) component. Previous analyses have found significant differences in tumor characteristics between pure IDC lacking DCIS and mixed IDC with DCIS. We will test our hypothesis that pure IDC represents a form of breast cancer with etiology and risk factors distinct from mixed IDC/DCIS.

Methods—We compared reproductive risk factors for breast cancer risk, as well as family and smoking history between 831 women with mixed IDC/DCIS (n=650) or pure IDC (n=181), and 1,620 controls, in the context of the Women's Circle of Health Study (WCHS), a case-control study of breast cancer in African-American and European-American women. Data on reproductive and lifestyle factors were collected during interviews, and tumor characteristics were abstracted from pathology reports. Case-control and case-case analyses were conducted using unconditional logistic regression.

Results—Most risk factors were similarly associated with pure IDC and mixed IDC/DCIS. However, among postmenopausal women, risk for pure IDC was lower in women with body mass index (BMI) 25 to <30 kg/m² (Odds Ratio (OR)=0.66; 95% confidence interval (CI), 0.35-1.23) and BMI ≥30 kg/m² (OR=0.33; 95% CI, 0.18-0.67) compared to women with BMI<25 kg/m², with no associations with mixed IDC/DCIS. In case-case analyses, women who breastfed up to 12 months (OR=0.55; 95% CI, 0.32-0.94) or longer (OR=0.47; 95% CI, 0.26-0.87) showed decreased odds of pure IDC than mixed IDC/DCIS compared to those who did not breastfeed.

Conclusions—Associations with some breast cancer risk factors differed between mixed IDC/DCIS and pure IDC, potentially suggesting differential developmental pathways. These findings, if confirmed in a larger study, will provide a better understanding of the development patterns of breast cancer and the influence of modifiable risk factors, which in turn could lead to better preventive measures for pure IDC, which have worse disease prognosis compared to mixed IDC/DCIS.

Keywords

Breast cancer; Ductal carcinoma in situ component; Risk factors; Cancer etiology; Cancer pathology

Background

Breast cancer develops as a result of multiple genetic changes in epithelial cells lining the mammary duct concurrent with changes in the surrounding stroma [1-3]. Invasive carcinoma is thought to develop through a linear succession of morphological changes from normal cells to atypical hyperplasia, to carcinoma *in situ*, and then becoming invasive as the lesion breaks through the basement membrane of the duct. However, breast cancer is a heterogeneous disease, and it is unlikely that all invasive breast tumors progress through the same course of development. Evidence suggests that for a proportion of carcinomas, progression is accelerated, resulting in the development of pure invasive ductal carcinoma (IDC) that either arise *de novo* or without an extended period of containment, often occurring between regular mammography screenings as interval tumors [4, 5]. Previous evidence suggests that IDC with accompanying DCIS may represent a distinct clinical and biological entity from pure IDC [6]. Pure invasive carcinoma, in comparison to mixed invasive carcinoma with DCIS, are larger, higher grade, have higher Ki-67 expression, fewer calcifications, and are more frequently negative for expression of estrogen receptor (ER) and human epidermal growth receptor 2 (HER2) [6-12]. Castro and colleagues found a substantial number of differentially expressed genes in pure DCIS compared with those expressed in mixed IDC/DCIS [13] and some studies suggest that the presence of a DCIS component is associated with cell-mediated immune changes in the microenvironment and neoplastic epithelial cells surrounding the DCIS leading to differences in tumor progression and improved prognosis [6, 9-10, 14-16]. Pure IDC has also been associated with younger age [7, 9, 10] and worse survival outcomes [7, 9, 17-18], although inconsistencies among studies for these factors exist [7-10, 17-18]. In addition, significant differences in the levels of matrix metalloproteinase expression have been observed between the tumor and stromal cells of mixed IDC/DCIS and pure IDC in histological studies [19, 20]. In sum, these differences in tumor characteristics and protein expression suggest potential differences in etiologic risk factors for mixed IDC/DCIS and pure IDC. Common risk factors for breast cancer, such as older age at menarche, nulliparity, older age at first birth, breast cancer in a first degree relative, and higher postmenopausal body mass index (BMI) are consistently associated with increased overall risk of invasive breast cancer [21-25], however, the impact of these factors on the presence or absence of concomitant DCIS remain largely unknown.

In this study, we evaluated potential risk factors associated with mixed IDC/DCIS and pure IDC in women in the Women's Circle of Health Study (WCHS), which was specifically designed to evaluate risk factors for early and aggressive breast cancer in African American (AA) compared to European American (EA) women [26-29]. We additionally examined screening practices and ER status to control for the possibility of an association between lack of screening and pure IDC, and the possibility that absence of a DCIS component is simply characteristic of ER negative tumors. Differences in risk factor profiles would provide evidence that mixed IDC/DCIS and pure IDC are biologically distinct diseases with potentially different etiologic pathways. A better understanding of the developmental patterns of breast cancer may offer more effective preventive measures and treatment options.

Methods

Study population and data

These analyses are based in the WCHS, a multi-center case-control study of breast cancer in AA and EA women, conducted in metropolitan New York City (NYC) from 2002 through 2008, and seven counties in New Jersey (NJ) from 2003 through 2012, which has been described in detail elsewhere [26-28]. Breast cancer cases in NYC were ascertained through 12 targeted hospitals and cases from NJ were identified through the NJ State Cancer Registry of the Department of Health through rapid case ascertainment. Eligible cases included English-speaking women who self-identified as AA or EA, 20 to 75 years of age, with a primary, newly diagnosed, histologically confirmed breast cancer. Controls without a history of any cancer diagnosis other than non-melanoma skin cancer were identified through random digit dialing (RDD) of residential telephone numbers and frequency matched by telephone prefixes of cases, a commonly accepted method for selecting controls in targeted areas to assemble a population comparable to cases [26-28]. The majority of cases were interviewed within 6 months of diagnosis, but were asked about behaviors prior to breast cancer diagnosis. In addition to recruitment by RDD, controls in NJ were also recruited through community-based efforts, mainly through churches and health events, with the help of community partners and advocates [28]. Community controls were on average less educated, had lower income, and were more likely to have Medicaid or Medicare as a form of insurance compared to RDD controls. Using data obtained by the American Community Survey of the United States Census Bureau, we showed within our study sample that a combination of controls recruited by RDD and from the community were more representative of the general AA community in New Jersey regarding education, income, marital status, and level of obesity, as an indicator of lifestyle factors, than RDD controls alone [28] and were a better comparison group to population-based cases recruited in NJ. Controls identified by RDD and community-based controls were frequency-matched to cases by self-reported race and 5-year age categories. In-person interviews were conducted to query participants on potential breast cancer risk factors and socioeconomic factors, including type of medical insurance and screening habits, and detailed anthropometric measurements were taken [28]. A signed release to obtain pathology data and tumor blocks was part of the informed consent process for cases, and data on hormone receptors, histology, grade and stage were abstracted from pathology reports by trained study staff. Protocols for agreement to participate and informed consent were approved by the Institutional Review Boards at Roswell Park Cancer Institute (RPCI), Rutgers Cancer Institute of New Jersey (CINJ), Icahn School of Medicine at Mount Sinai School (ISMMSS; formerly the Mount Sinai School of Medicine) and the participating hospitals in NYC in compliance with the Declaration of Helsinki.

Out of a total of 1,513 women with breast cancer in the WCHS, women were excluded if they were diagnosed with pure DCIS (n=258), invasive carcinomas of other types (n=141), or cancers with unknown histology (n=283, 53 cases of which were excluded because presence or absence of DCIS with IDC could not be determined). Records of pure IDC patients were included only when medical reports clearly stated that there was no DCIS component, or included detailed descriptions of hyperplasia without mention of DCIS. In

addition, slides of tumor samples from cases were reviewed by two breast pathologists to verify presence or absence of DCIS. Included in the final study were 831 women with IDC (recognized as *ductal carcinoma of no special type* in accordance with World Health Organization terminology) or mixed IDC/invasive lobular carcinoma and 1,620 controls.

Statistical Analyses

Differences between controls, and cases with pure IDC or mixed IDC/DCIS were compared using Student's t-test for continuous variables and chi-squared tests for categorical variables. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) and p-values were calculated to estimate associations between risk factors and mixed IDC/DCIS or pure IDC in case-control multivariable models using unconditional logistic regression. Analyses were conducted for AA and EA women combined, which included adjustments for self-reported race. Potential interactions by race were also assessed by introducing cross-product terms (race x exposure) into the logistic regression model for all women combined. Case-case analyses, using unconditional logistic regression, were performed to determine if risk factors were differentially associated with odds of being diagnosed with pure IDC ("case") compared to odds of being diagnosed with mixed IDC/DCIS ("control"). Since AA women are more likely to be diagnosed with more aggressive breast cancers compared to EA women, and risk factors for breast cancer may have differential effects in EA and AA women [29-31], case-case findings were also stratified by self-reported race to determine if observed associations are modified by race. Wald's Chi-square was used to calculate p-values for categorical variables. P-trends were calculated using median values for each category or quantile.

Risk factors evaluated included family history, defined as having a first degree relative with breast cancer, age at menarche, parity, oral contraceptive (OC) use, menopausal hormone therapy (MHT) use, current BMI, smoking, age at first birth, age at last birth, number of births, and total breastfeeding duration. Categories for duration of OC use (1-72 months, > 72 months) were defined by months of use associated with increased breast cancer risk in this and previous studies [32]. Categories of age at first and last birth were created using cutoffs from previous literature [29, 30] that allowed for adequate sample sizes within both AA and EA groups, since AA women were more likely to have earlier age at first birth as well as earlier age at last birth. ORs estimating associations with age at first birth, age at last birth, number of births and breastfeeding were calculated among parous women only. BMI was calculated as kg/m², using weight and height measurements collected during home interviews. Categories of <25, 25 to <30, and ≥ 30 kg/m² were chosen for BMI, corresponding to normal and underweight, overweight, and obesity, respectively. Underweight women were included in the analyses, but were not considered as a separate category due to their small number. Data were stratified by menopausal status for examination of BMI due to differential effects of BMI on pre- and postmenopausal breast cancer risk in previous studies [28]. Women were considered premenopausal if they had either periods within the last year or at least one remaining ovary and were under the age of 50, the median age for natural menopause in the WCHS. Otherwise, women without periods within the last year were considered postmenopausal. Multivariable analyses were performed to account for potential confounding factors selected *a priori*. Models were

adjusted for age, race, birthplace, family history, education, OC use, age at menarche, parity and menopausal status (unless they were the main variable of interest), given their known associations with breast cancer risk and/or reproductive history. Place of birth was included in our models because women born outside of the United States tended to have more children, were more likely to have breastfed, and were more likely to be diagnosed with more aggressive disease compared to women born in the United States. Because less frequent screening may lead to the detection of more advanced lesions, and because the identification of a DCIS component may be inversely associated with later stage disease, we also adjusted for screening history using a composite screening score. The score was based on responses to three questions: 1) whether the participant had ever had a physician breast examination, 2) had self-examined breasts for lumps, or 3) had ever received a mammogram. Each screening measure was assigned 1 point, for a score of 3 for a woman who reported ever using all 3 screening measures. Age at first birth was included when factors associated with reproduction were assessed, and self-reported race was included when AA and EA women were combined. In case-case analyses between pure IDC and mixed IDC/DCIS, a third model with additional adjustments for ER status is shown since pure IDC was strongly associated with ER negative cancers in our study population.

Additional case-case analyses comparing tumor characteristics of pure IDC and mixed IDC/DCIS were conducted using unconditional logistic regression. Variables describing tumor characteristics included age, tumor size, tumor grade, stage, lymph node (LN) status, lymphovascular invasion (LVI), ER status, progesterone (PR) status, HER2 status and method of breast cancer discovery. Models were adjusted as described above for case-control analyses.

Breast cancer subtypes were approximated from ER, PR and HER2 status. Tumors with positive ER or PR status were categorized as luminal A or B, depending on negative or positive HER2 status, respectively. Tumors with a negative ER and PR status were categorized as triple negative or HER2 overexpressing breast cancer, depending on negative or positive HER2 status, respectively.

Sensitivity analyses were conducted to examine proportions of pure IDC and mixed IDC/DCIS across different hospitals to determine if reporting of pure IDC and mixed IDC/DCIS varied between institutions. The potential impact of heterogeneity across institutions on risk estimates were assessed by removing cases from each specific hospital, in turn, to determine if associations were affected. All analyses were performed using SAS 9.2.

Results

Characteristics of women with breast cancer according to pure IDC and mixed IDC/DCIS, as well as controls, are shown in Table 1, along with unadjusted odds ratios (OR) and 95% confidence intervals (CI) for developing pure IDC and mixed IDC/DCIS. Women with pure IDC constituted 21.8% of women with invasive breast cancer. Sixty-three percent of women with pure IDC were AA, compared to 53.5% of women with mixed IDC/DCIS (P=0.05). Women with pure IDC were more likely to have a high school education or less (43% pure IDC vs. 33% mixed IDC/DCIS, P=0.02).

Case-control associations with breast cancer risk factors

Case-control comparisons are shown for pure IDC and mixed IDC/DCIS in Table 2. Overall, women with a family history of breast cancer had greater odds of being diagnosed with pure IDC (OR=1.54; 95% CI, 1.02-2.34) or mixed IDC/DCIS (OR=1.44; 95% CI, 1.12-1.85) compared to those without a family history. OC use was associated with increased odds of mixed IDC/DCIS compared to nonusers (OR=1.30; 95% CI, 1.02-1.66 for over 72 months of OC use; p-trend=0.03), with a similar, but non-significant associations and trend for pure IDC (OR=1.36; 95% CI, 0.91-2.05 for over 72 months of OC use; p-trend=0.16). Postmenopausal women with BMI ≥ 30 compared to those with BMI < 25 kg/m² had a reduced risk of pure IDC (OR=0.35; 95% CI, 0.18-0.67; p-trend=0.02), but no associations were observed with mixed IDC/DCIS (p-trend=0.58). Women with last birth later than age 33 also had reduced risk of pure IDC (OR=0.59; 95% CI, 0.37-0.93; p-trend=0.04), but not mixed IDC/DCIS (OR=0.85; 95% CI, 0.65-1.10), compared to women who had their last birth by age 22. There was some indication that women who had breastfed 12 months or longer were less likely to be diagnosed with pure IDC compared to women who did not breastfeed (p-trend=0.07). No associations, however, were observed between breast feeding and risk of being diagnosed with mixed IDC/DCIS (p-trend=0.49). There was some indication that risk of pure IDC or mixed IDC/DCIS may differ by race for OC use, BMI among postmenopausal women, parity, and age at last birth. In fully adjusted models, risk of pure IDC was greater with OC use over 72 months among AA women (OR=1.75; 95% CI, 1.05-2.92), but not among EA women (OR=0.99; 95% CI, 0.51-1.95; p-interaction = 0.18) (See Supplementary Table 1). Odds of mixed IDC/DCIS was similarly increased with longer OC use among AA women (OR=1.69; 95% CI, 1.21-2.36), but not among EA women (OR=0.96; 95% CI, 0.67-1.38; p-interaction=0.02) (See Supplementary Table 2). Among postmenopausal women, higher BMI was found to be protective for pure IDC only among AA women (≥ 30 vs < 25 kg/m², OR=0.22; 95% CI, 0.10-0.51; p-interaction = 0.08). There was some indication that increasing parity was protective for pure IDC (OR=0.46; 95% CI, 0.21-1.01; p-interaction =0.24) and mixed IDC/DCIS (OR=0.61; 95% CI, 0.40-0.93; p-interaction=0.82) among EA women, but not among AA women, and older age at last birth was protective for pure IDC, but only among AA women (> 33 vs ≤ 28 years, OR=0.48; 95% CI, 0.28-0.85; p-interaction = 0.24).

Case-case associations with breast cancer risk factors

Case-case analyses comparing pure IDC to mixed IDC/DCIS as the “control” group are shown in Table 3. EA women were less likely to be diagnosed with pure IDC compared to mixed IDC/DCIS in the age-adjusted model (OR=0.72; 95% CI, 0.52-1.01), however, this association was null in the fully-adjusted model, largely attributable to additional adjustment for ER status (OR=1.07; 95% CI, 0.67-1.72, Model 3). Postmenopausal women with BMI ≥ 30 kg/m² were less likely to be diagnosed with pure IDC than mixed IDC/DCIS (OR=0.38; 95% CI, 0.19-0.79; p-trend=0.01) compared to women with BMI < 25 kg/m². Women who were current or former smokers were less likely to be diagnosed with pure IDC than mixed IDC/DCIS (OR=0.68; 95% CI, 0.45-1.01), however, this association was only of borderline significance. Women who breastfed up to 12 months (OR=0.55; 95% CI, 0.32-0.94) or longer (OR=0.47; 95% CI, 0.36-0.87) were approximately 50% less likely to be diagnosed

with pure IDC than with mixed IDC/DCIS (p-trend=0.18) compared to women who did not breastfeed.

We additionally compared case-case associations stratified by race to see if risk factors were similarly associated in both AA and EA populations (Table 4). Among AAs, postmenopausal women with BMI >30 kg/m² showed significantly reduced odds of pure IDC (OR=0.33; 95% CI, 0.13-0.86) compared to those with BMI ≤ 25 kg/m²; no differences were observed among EA women. ORs below unity were also observed among EA women who breastfed up to 12 months (OR=0.34; 95% CI, 0.14-0.84) or longer (OR=0.37; 95% CI, 0.14-1.03) compared to women who did not breastfeed (p-trend=0.25), with similar, but non-significant findings among AA women. Race-stratified analyses were limited by small sample size, particularly among EA women, with only 67 cases of pure IDC. Interactions with race were not observed in case-case analyses.

Case-case associations with tumor characteristics

When associations with tumor characteristics were examined, tumors larger than 2 cm were more likely to be pure IDC than mixed IDC/DCIS (OR=1.58; 95% CI, 1.07- 2.35 for tumors 2 to <5 cm; OR= 2.16; 95% CI, 1.00-4.67 for tumors ≥ 5 cm) (Table 5). In addition to tumor size, ER negative tumors were also associated with increased odds of pure IDC (OR=2.79; 95% CI, 1.93-4.05), while positive LN status (OR=0.55; 95% CI, 0.35-0.87) and LVI (OR=0.58; 95% CI, 0.36-0.92) were associated with reduced odds of pure IDC. Triple negative tumors were over 3 times more likely to be pure IDC than mixed IDC/DCIS (OR=3.26; 95% CI, 2.08-5.12). Tumors discovered by palpation rather than mammogram were more likely to be pure IDC than mixed IDC/DCIS (OR=1.54; 95% CI, 1.02-2.32). A significant interaction between race and tumor grade in association with pure IDC was observed; EA women with higher grade tumors were more likely to have pure IDC (OR=3.94; 95% CI, 1.32-11.7), whereas higher grade was not associated with pure IDC among AA women (OR=1.38; 95% CI, 0.81-2.37; p-interaction=0.02) (Data not shown).

Case-case risk factor associations stratified by ER status

When stratified by ER status (Supplementary Table 3), reduced odds of being diagnosed with pure IDC compared to mixed IDC/DCIS were noted for ER negative breast cancers among postmenopausal women with BMI ≥ 30 compared to women with BMI<25. Greater time spent breastfeeding was similarly associated with lower odds of pure IDC among women with ER positive and ER negative breast cancers. Associations, however, were not statistically significant for EA women, likely due in part to sample size limitations. Interactions by ER status were not statistically significant.

Discussion

There are few reported studies in the literature investigating potential differences between pure IDC and mixed IDC/DCIS for invasive breast cancers [2, 6-9, 11, 17]. We hypothesized that risk factors for pure IDC may differ from those for mixed IDC/DCIS if these cancers are biologically distinct from one another [6]. Identification of a distinct risk factor profile for pure IDC could target women who should be more closely screened to

prevent pure IDC tumors, which have been shown to be associated with poorer prognosis than mixed IDC/DCIS [6-11]. To our knowledge, this is the first study to examine risk factors associated with pure IDC versus mixed IDC/DCIS. In this case-control study of breast cancer in AA and EA women, we found that higher BMI among postmenopausal women, older age at last birth, and longer duration of breastfeeding among parous women were protective for pure IDC, but not for mixed IDC/DCIS.

Demographic characteristics differed between pure IDC and mixed IDC/DCIS as well. Women with more education, and more extensive history of breast cancer screening were less likely to have pure IDC than mixed IDC/DCIS. This is similar to findings for women with ER negative breast cancer compared to women with ER positive breast cancer, who were found to have attained less education and were screened less often [33]. Likewise, Starks et al. found that breast cancer patients with p53 mutations were more likely to have lower incomes, and suggested that a lifetime of exposures associated with socioeconomic status might result in different breast cancer etiologies [34]. To reduce potential bias resulting from an association between later detection and pure IDC diagnosis, we adjusted our models for screening history and education level.

Tumor characteristics differed between pure IDC and mixed IDC/DCIS in this and previous studies [5-6, 10]. Pure IDC cases were not only more likely to be ER negative, but women with pure IDC were also less likely to have lymph node involvement or LVI. Previous studies have found pure IDC tumors to have higher Ki-67 expression [6], fewer associated calcifications [10], and a greater likelihood of being an interval breast cancer [5]. Pure IDC may show tumor characteristics associated with a fast-growing tumor etiology, with fewer cases of lymph node involvement among women with less education and possibly lower socioeconomic status.

Postmenopausal women with normal or lower BMIs were more likely to be diagnosed with pure IDC than mixed IDC/DCIS in our study. After menopause, when estrogen is no longer produced by the ovaries, adipose tissue is the depot for conversion of androgens to estrogens through aromatase activity [36-37]. Estrogens are known to be related to breast cancer risk, and it is thought that higher risk with greater BMI in postmenopausal women is mediated through this mechanism [38]. Most studies show a greater association between risk and BMI among women with ER positive breast cancer [39-42], although there are studies with discrepant findings [35, 43-44]. There were no associations observed between mixed IDC/DCIS and BMI in this study. In case-control analyses, we found that higher BMI among postmenopausal women was unexpectedly associated with decreased odds of pure IDC, which is in contrast to previous studies looking at all breast cancers combined [38], suggesting that pure IDC may represent a subset of breast cancer with unique risk factors. A decreased risk of overall invasive breast cancer was observed among postmenopausal AA women with BMI ≥ 25 in the Black Women's Health Study, similar to the decreased risk for pure IDC observed among postmenopausal AA women in our study [44]. It is known that BMI influences metabolic pathways [45] and subsequently may influence cancer development and progression [46]. In one follow-up study of 2,092 breast cancer survivors, women with metabolic syndrome were twice as likely to experience distant metastasis [47]. It is possible that BMI measured at baseline might have been affected by breast cancer

treatment since home interviews with anthropometric measurements were conducted approximately 6 months after diagnosis. Potential bias from the effect of treatment on BMI, however, cannot explain the different estimates found between pre- and postmenopausal women.

We observed an inverse association between breastfeeding and pure IDC compared to mixed IDC/DCIS. Breastfeeding appears to be modestly protective for breast cancer [48-50], but seems to be substantially more protective against the more aggressive breast cancer subtypes, including hormone-receptor negative and basal-like cancers in most [29, 51-54], but not all studies [30, 55]. Mechanisms postulated for these effects include the reduction of ovulatory cycles, induction of breast differentiation, and the presence of human milk complex of alpha-lactalbumin and oleic acid (HAMLET) secreted in milk that causes tumor cells to undergo apoptosis [56-60]. Women with an older age at last birth also had reduced odds of pure IDC, contrary to the noted increase in breast cancer risk in women up to 10 years after pregnancy [61]. More studies are needed to examine reproductive factors associated with breast cancer in AA women compared to EA women.

Previous studies describe an association between ER negative breast cancer and pure IDC [6, 11]. Because pure IDC tumors are more likely to be ER negative, the observed association between breastfeeding and reduced odds of pure IDC in relation to mixed IDC may be similar to previous studies showing a greater protective effect of breastfeeding against ER negative tumors [29, 51-54]. However, despite the strong association of pure IDC with negative ER status, observations after stratification by ER status indicated that the association between longer duration of breastfeeding and reduced risk of pure IDC did not depend upon ER status, and therefore unlikely to be mediated by estrogen-related pathways.

AA breast cancer patients present more often than EA patients with positive LNs and tumors that are larger, higher grade, ER negative, and later stage, i.e. characteristics associated with a poor prognosis [62-66]. Because disease characteristics associated with pure IDC are also more common in AA women, the presence or absence of a DCIS component may reflect a distinct natural history that could account for some of the differences observed between AA and EA patients. In our study, AA women with breast cancer were more likely to have pure IDC than mixed IDC/DCIS, but observed associations between breast cancer risk factors and risk of pure IDC or mixed IDC/DCIS, with the exception of OC use, BMI among postmenopausal women, parity, and age at last birth, were not found to be differential by race. Once adjustment for demographic and breast cancer risk factors were added to the model, however, the increased odds of pure IDC among AA women was attenuated, suggesting that the development of pure IDC versus mixed IDC/DCIS is related, in part, to different risk factor and demographic profiles. The higher occurrence of pure IDC due to these factors may account for some of the disparities observed in breast cancer characteristics between AA and EA women.

Strengths of this study include the large number of participants and extensive information provided by in-person interviews, pathology reports and tumor samples available in the WCHS, allowing for the examination of several risk factors and tumor characteristics with adjustment for potential confounders. Rarer forms of breast cancer were not included and

cases were limited to invasive tumors with ductal histology so that analyses could be focused on a set of tumors with more similar etiologies and prognosis. Finally, this is the first study of our knowledge that has examined the association of breast cancer risk factors and the presence or absence of an *in situ* component concomitant to invasive carcinoma, which could affect disease prognosis. In addition, we had the benefit of looking at associations within AA and EA women.

Several potential limitations should be noted when interpreting this data. First, missing data on the histology of breast tumors led to the exclusion of 30% of cases from our analyses, which could have biased our findings if records between pure IDC and mixed IDC/DCIS were differentially or systematically missing from a group of women that shared similar risk factors. We compared tumor characteristics and risk factors between WCHS participants with and without missing histologies and found no significant differences. ER status, tumor size, breastfeeding and BMI in women with missing tumor histologies were intermediate between women with pure IDC and mixed IDC/DCIS, suggesting a similar proportion of women with missing data among women with pure IDC and mixed IDC/DCIS. Secondly, lack of standardization of pathology reports collected from a number of different hospitals may have introduced misclassification, possibly attenuating associations if misclassifications were non-differential across our variables of interest. Analyses of pure IDC and mixed IDC/DCIS diagnoses at individual hospitals did not identify any significant differences in the proportion of pure IDC to mixed IDC/DCIS to indicate reporting biases stemming from pathology reports. Additionally, two breast pathologists reviewed selected slides from registered cases to verify the presence or absence of DCIS. Some hospitals did report greater numbers of women with negative ER status, which may reflect possible differences in the reporting of ER status or true underlying differences in the patient populations served. Finally, bias may have been introduced with earlier detection of mixed IDC/DCIS compared to pure IDC if women with mixed IDC/DCIS are more likely to obtain screening mammography. Women with pure IDC, who tend to be less educated, may have lower access to screening and present at a later disease stage with larger cancers, although this does not explain why women with pure IDC were less likely to have positive lymph node status. To reduce potential bias resulting from screening, we included a screening score in our models and adjusted for education, although residual confounding may still have occurred since the score only contained information on ever screening behavior rather than screening behavior close in time to the cancer diagnosis.

Conclusions

In conclusion, breast cancer has been described as a heterogeneous disease based upon a range of genetic factors, molecular profiles, and clinical manifestations. The presence or absence of a DCIS component, a tumor characteristic associated with breast cancer outcomes, may represent different etiologic pathways for breast cancer. Some risk factors varied significantly between cases with pure IDC and mixed IDC/DCIS. Although a portion of pure IDC cancers may have progressed from mixed IDC/DCIS cancers, the absence of a DCIS component may also represent a tumor type with a distinctive developmental pathway, associated with lower BMI in postmenopausal women and shorter breastfeeding duration. These findings need to be confirmed in a larger study. Understanding of modifiable risk

factors associated with reduced risk of pure IDC can potentially be applied to preventing this breast cancer subtype.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This work was supported by grants from the US Army Medical Research and Materiel Command (DAMD-17-01-1-0334) (to D.H. Bovbjerg and C.B. Ambrosone), the National Cancer Institute (R03 CA17106 to C.B. Ambrosone; R01 CA100598 to C.B. Ambrosone; P01 CA151135 to C.B. Ambrosone, J.R. Palmer and A.F. Olshan; K22 CA138563 to E.V. Bandera; P30 CA072720 to Roswell Park Cancer Institute; P30 CA016056 to Rutgers Cancer Institute of NJ), the Breast Cancer Research Foundation (to C.B. Ambrosone) and a gift from the Philip L. Hubbell family (to C.B. Ambrosone). The New Jersey State Cancer Registry (NJSCR) is a participant in the Centers for Disease Control and Prevention's National Program of Cancer Registries and is a National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Expansion Registry. The NJSCR is supported by the Centers for Disease Control and Prevention under cooperative agreement 5U58DP003931-02 awarded to the New Jersey Department of Health. The collection of New Jersey cancer incidence data is also supported by the National Cancer Institute's SEER Program under contract N01PC-2013-00021 and the State of New Jersey. The funding agents played no role in the study design, data collection, analysis, and interpretation of data, or in the writing of the manuscript for publication.

List of abbreviations

IDC	invasive ductal carcinoma
DCIS	ductal carcinoma in situ
AA	African-American
WCHS	Women's Circle of Health
EA	European-American
BMI	body mass index
OR	Odds Ratio
CI	confidence interval
ER	estrogen receptor
HER2	human epidermal growth factor-2
LN	lymph node
RPCI	Roswell Park Cancer Institute
CINJ	Rutgers Cancer Institute of New Jersey
ISMSS	Icahn School of Medicine at Mount Sinai School
OC	oral contraceptive
MHT	menopausal hormone therapy
HAMLET	human milk complex of alpha-lactalbumin and oleic acid

References

1. Wellings SR, Jensen HM. On the origin and progression of ductal carcinoma in the human breast. *J Natl Cancer Inst.* 1973; 50:1111–1118. [PubMed: 4123242]
2. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, Mohsin SK, O'Connell P, Tsimelzon A, Medina D. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. *Clin Cancer Res.* 2008; 14:370–378. [PubMed: 18223211]
3. Schedin P, Elias A. Multistep tumorigenesis and the microenvironment. *Breast Cancer Res.* 2004; 126:93–101. [PubMed: 14979914]
4. Esserman LJ, Shieh Y, Rutgers EJ, Knauer M, Retel VP, Mook S, Glas AM, Moore DH, Linn S, van Leeuwen FE, van 't Veer LJ. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. *Breast Cancer Res Treat.* 2011; 130:725–734. [PubMed: 21892702]
5. Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E. Breast tumor characteristics as predictors of mammographic detection: Comparison of interval- and screen-detected cancers. *J Natl Cancer Inst.* 1999; 91:2020–2028. [PubMed: 10580027]
6. Wong H, Lau S, Yau T, Cheung P, Epstein RJ. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. *Br J Cancer.* 2010; 102:1391–1396. [PubMed: 20424617]
7. Silverberg SG, Chitale AR. Assessment of significance of proportions of intraductal and infiltrating tumor growth in ductal carcinoma of the breast. *Cancer.* 1973; 32:830–837. [PubMed: 4356480]
8. Logullo AF, Godoy AB, Mourao-Neto M, Simpson AJ, Nishimoto IN, Brentani MM. Presence of ductal carcinoma in situ confers an improved prognosis for patients with T1N0M0 invasive breast carcinoma. *Braz J Med Biol Res.* 2002; 35:913–919. [PubMed: 12185383]
9. Chagpar AB, McMasters KM, Sahoo S, Edwards MJ. Does ductal carcinoma in situ accompanying invasive carcinoma affect prognosis? *Surgery.* 2009; 146:561–7. discussion 567-8. [PubMed: 19789013]
10. Jiang X, Ma T, Moran MS, Kong X, Li X, Haffty BG, Yang Q. Mammographic features are associated with clinicopathological characteristics in invasive breast cancer. *Anticancer Res.* 2011; 31:2327–2334. [PubMed: 21737659]
11. Wong H, Lau S, Leung R, Chiu J, Cheung P, Wong TT, Liang R, Epstein RJ, Yau T. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer. *Med Oncol.* 2012; 29:1536–1542. [PubMed: 21983862]
12. Kim JY, Han W, Moon HG, Park IA, Ahn SK, Kim J, Lee JW, Kim T, Kim MK, Noh DY. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor. *Clin Breast Cancer.* 2013; 13:385–91. [PubMed: 23870857]
13. Castro NP, Osorio CA, Torres C, Bastos EP, Mourao-Neto M, Soares FA, Brentani HP, Carraro DM. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. *Breast Cancer Res.* 2008; 10:R87. [PubMed: 18928525]
14. Lakhani SR, O'Hare MJ. The mammary myoepithelial cell – Cinderella or ugly sister? *Breast Cancer Res.* 2001; 3:1–4. [PubMed: 11250738]
15. Barsky SH, Karlin NJ. Mechanisms of disease: breast tumor pathogenesis and the role of the myoepithelial cell. *Nat Clin Pract Oncol.* 2006; 3:138–151. [PubMed: 16520804]
16. Black MM, Zachrau RE, Hankey BF, Feuer EJ. Prognostic significance of in situ carcinoma associated with invasive breast carcinoma. A natural experiment in cancer immunology? *Cancer.* 1996; 78:778–788. [PubMed: 8756372]
17. Carabias-Meseguer P, Zapardiel I, Cusidó-Gimferrer M, Godoy-Tundidor S, Tresserra-Casas F, Rodríguez-García I, Fábregas-Xauradó R, Xercavins-Montosa J. Influence of the in situ component in 389 infiltrating ductal breast carcinomas. *Breast Cancer.* 2013; 20:213–7. [PubMed: 22271067]
18. Mylonas I, Makovitzky J, Jeschke U, Briese V, Friese K, Gerber B. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone. *Anticancer Res.* 2005; 25(3A):1719–23. [PubMed: 16033090]

19. Gonzalez LO, Junquera S, del Casar JM, Gonzalez L, Marin L, Gonzalez-Reyes S, Andicoechea A, Gonzalez-Fernandez R, Gonzalez JM, Perez-Fernandez R, Vizoso FJ. Immunohistochemical study of matrix metalloproteinases and their inhibitors in pure and mixed invasive and in situ ductal carcinomas of the breast. *Hum Pathol.* 2010; 41:980–989. [PubMed: 20236691]
20. Lebeau A, Muller-Aufdemkamp C, Allmacher C, Sauer U, Nerlich A, Lichtinghagen R, Lohrs U. Cellular protein and mRNA expression patterns of matrix metalloproteinases-2, -3 and -9 in human breast cancer: Correlation with tumour growth. *J Mol Histol.* 2004; 35:443–455. [PubMed: 15571322]
21. Lambe M, Hsieh CC, Chan HW, Ekblom A, Trichopoulos D, Adami HO. Parity, age at first and last birth, and risk of breast cancer: A population-based study in Sweden. *Breast Cancer Res Treat.* 1996; 38:305–311. [PubMed: 8739084]
22. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. *Cancer Epidemiol Biomarkers Prev.* 2004; 13:1558–68.
23. Lord SJ, Bernstein L, Johnson KA, Malone KE, McDonald JA, Marchbanks PA, Simon MS, Strom BL, Press MF, Folger SG, Burkman RT, Deapen D, Spirtas R, Ursin G. Breast cancer risk and hormone receptor status in older women by parity, age of first birth, and breastfeeding: A case-control study. *Cancer Epidemiol Biomarkers Prev.* 2008; 17:1723–1730. [PubMed: 18628424]
24. Van Den Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom AR, Fraser G, Goldbohm RA, Graham S, Kushi L, Marshall JR, Miller AB, Rohan T, Smith-Warner SA, Speizer FE, Willett WC, Wolk A, Hunter DJ. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. *Am J Epidemiol.* 2000; 152:514–527. [PubMed: 10997541]
25. Mahoney MC, Bevers T, Linos E, Willett WC. Opportunities and strategies for breast cancer prevention through risk reduction. *CA Cancer J Clin.* 2008; 58:347–71. [PubMed: 18981297]
26. Ambrosone CB, Ciupak GL, Bandera EV, Jandorf L, Bovbjerg DH, Zirpoli G, Pawlish K, Godbold J, Furberg H, Fatone A, Valdimarsdottir H, Yao S, Li Y, Hwang H, Davis W, Roberts M, Sucheston L, Demissie K, Amend KL, Tartter P, Reilly J, Pace BW, Rohan T, Sparano J, Raptis G, Castaldi M, Estabrook A, Feldman S, Weltz C, Kemeny M. Conducting molecular epidemiological research in the age of HIPAA: A multi-institutional case-control study of breast cancer in African-American and European-American women. *J Oncol.* 2009; 2009:871250. [PubMed: 19865486]
27. Ruiz-Narvaez EA, Rosenberg L, Yao S, Rotimi CN, Cupples AL, Bandera EV, Ambrosone CB, Adams-Campbell LL, Palmer JR. Fine-mapping of the 6q25 locus identifies a novel SNP associated with breast cancer risk in African-American women. *Carcinogenesis.* 2013; 34:287–291. [PubMed: 23104177]
28. Bandera EV, Chandran U, Zirpoli G, McCann SE, Ciupak G, Ambrosone CB. Rethinking sources of representative controls for the conduct of case-control studies in minority populations. *BMC Med Res Methodol.* 2013; 13:71–2288-13-71. [PubMed: 23721229]
29. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM. Epidemiology of basal-like breast cancer. *Breast Cancer Res Treat.* 2008; 109:123–139. [PubMed: 17578664]
30. Ursin G, Bernstein L, Lord SJ, Karim R, Deapen D, Press MF, Daling JR, Norman SA, Liff JM, Marchbanks PA, Folger SG, Simon MS, Strom BL, Burkman RT, Weiss LK, Spirtas R. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. *Br J Cancer.* 2005; 93:364–371. [PubMed: 16079783]
31. Hall IJ, Moorman PG, Millikan RC, Newman B. Comparative analysis of breast cancer risk factors among African-American women and White women. *Am J Epidemiol.* 2005; 161:40–51. [PubMed: 15615914]
32. Beaber EF, Malone KE, Tang MT, Barlow WE, Porter PL, Daling JR, Li CI. Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. *Cancer Epidemiol Biomarkers Prev.* 2014; 23:755–764. [PubMed: 24633144]
33. Kohler BA, Sherman RL, Howlander N, Jemal A, Ryerson AB, Henry KA, Boscoe FP, Cronin KA, Lake A, Noone AM, Henley SJ, Ehemann CR, Anderson RN, Penberthy L. Annual Report to the

- Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. *J Natl Cancer Inst.* 2015; 107:djv048. [PubMed: 25825511]
34. Starks AM, Martin DN, Dorsey TH, Boersma BJ, Wallace TA, Ambs S. Household income is associated with the p53 mutation frequency in human breast tumors. *PLoS One.* 2013; 8:e57361. [PubMed: 23469190]
 35. Vona-Davis L, Rose DP, Hazard H, Howard-McNatt M, Adkins F, Partin J, Hobbs G. Triple-negative breast cancer and obesity in a rural Appalachian population. *Cancer Epidemiol Biomarkers Prev.* 2008; 7:3319–3324.
 36. Key T, Appleby P, Barnes I, Reeves G. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. *J Natl Cancer Inst.* 2002; 94:606–616. [PubMed: 11959894]
 37. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT, Allen NE, Bueno-de-Mesquita HB, van Gils CH, Grobbee D, Boeing H, Lahmann PH, Nagel G, Chang-Claude J, Clavel-Chapelon F, Fournier A, Thiebaut A, Gonzalez CA, Quiros JR, Tormo MJ, Ardanaz E, Amiano P, Krogh V, Palli D, Panico S, Tumino R, Vineis P, Trichopoulou A, Kalapothaki V, Trichopoulos D, Ferrari P, Norat T, Saracci R, Riboli E. Postmenopausal serum androgens, oestrogens and breast cancer risk: The European prospective investigation into cancer and nutrition. *Endocr Relat Cancer.* 2005; 12:1071–1082. [PubMed: 16322344]
 38. Cheraghi Z, Poorolajal J, Hashem T, Esmailnasab N, Doosti Irani A. Effect of body mass index on breast cancer during premenopausal and postmenopausal periods: A meta-analysis. *PLoS One.* 2012; 7:e51446. [PubMed: 23236502]
 39. Suzuki R, Rylander-Rudqvist T, Ye W, Saji S, Wolk A. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study. *Int J Cancer.* 2006; 119:1683–1689. [PubMed: 16646051]
 40. Kawai M, Kakugawa Y, Nishino Y, Hamanaka Y, Ohuchi N, Minami Y. Anthropometric factors, physical activity, and breast cancer risk in relation to hormone receptor and menopausal status in Japanese women: A case-control study. *Cancer Causes Control.* 2013; 24:1033–1044. [PubMed: 23494727]
 41. Bao PP, Shu XO, Gao YT, Zheng Y, Cai H, Deming SL, Ruan ZX, Su Y, Gu K, Lu W, Zheng W. Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the Shanghai breast cancer study. *Am J Epidemiol.* 2011; 174:661–671. [PubMed: 21768404]
 42. Canchola AJ, Anton-Culver H, Bernstein L, Clarke CA, Henderson K, Ma H, Ursin G, Horn-Ross PL. Body size and the risk of postmenopausal breast cancer subtypes in the California teachers study cohort. *Cancer Causes Control.* 2012; 23:473–485.
 43. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Stefanick ML, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Vitolins M, Kabat GC, Rohan TE, Li CI. Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. *Cancer Epidemiol Biomarkers Prev.* 2011; 20:454–463. [PubMed: 21364029]
 44. Palmer JR, Adams-Campbell LL, Boggs DA, Wise LA, Rosenberg L. A prospective study of body size and breast cancer in Black women. *Cancer Epidemiol Biomarkers Prev.* 2007; 16:1795–1802. [PubMed: 17855697]
 45. Shetty PS, Soares MJ, James WP. Body mass index: its relationship to basal metabolic rates and energy requirements. *Eur J Clin Nutr.* 1994; 48:S28–37. [PubMed: 7843158]
 46. Budczies J, Denkert C, Muller BM, Brockmoller SF, Klauschen F, Gyorffy B, Dietel M, Richter-Ehrenstein C, Marten U, Salek RM, Griffin JL, Hilvo M, Oresic M, Wohlgemuth G, Fiehn O. Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue - a GC-TOFMS based metabolomics study. *BMC Genomics.* 2012; 13:334–2164-13-334. [PubMed: 22823888]
 47. Berrino F, Villarini A, Traina A, Bonanni B, Panico S, Mano MP, Mercandino A, Galasso R, Barbero M, Simeoni M, Bassi MC, Consolaro E, Johansson H, Zarcione M, Bruno E, Gargano G, Venturelli E, Pasanisi P. Metabolic syndrome and breast cancer prognosis. *Breast Cancer Res Treat.* 2014; 147:159–165. [PubMed: 25104441]
 48. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and breastfeeding: Collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries,

- including 50302 women with breast cancer and 96973 women without the disease. *Lancet*. 2002; 360:187–195. 41. [PubMed: 12133652]
49. Yang L, Jacobsen KH. A systematic review of the association between breastfeeding and breast cancer. *J Womens Health (Larchmt)*. 2008; 17:1635–45. [PubMed: 19049358]
50. Faupel-Badger JM, Arcaro KF, Balkam JJ, Eliassen AH, Hassiotou F, Lebrilla CB, Michels KB, Palmer JR, Schedin P, Stuebe AM, Watson CJ, Sherman ME. Postpartum remodeling, lactation, and breast cancer risk: summary of a National Cancer Institute-sponsored workshop. *J Natl Cancer Inst*. 2013; 105:166–74. [PubMed: 23264680]
51. Shinde SS, Forman MR, Kuerer HM, Yan K, Peintinger F, Hunt KK, Hortobagyi GN, Pusztai L, Symmans WF. Higher parity and shorter breastfeeding duration: Association with triple-negative phenotype of breast cancer. *Cancer*. 2010; 116:4933–4943. [PubMed: 20665494]
52. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. *Cancer*. 2008; 113:1521–1526. [PubMed: 18726992]
53. Palmer JR, Boggs DA, Wise LA, Ambrosone CB, Adams-Campbell LL, Rosenberg L. Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. *Cancer Epidemiol Biomarkers Prev*. 2011; 20:1883–1891. [PubMed: 21846820]
54. Ambrosone CB, Zirpoli G, Ruszczyk M, Shankar J, Hong CC, Roberts M, Yao S, McCann SE, Ciupak G, Hwang H, Khoury T, Jandorf L, Bovbjerg DH, Pawlish K, Bandera EV. Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen and progesterone receptor status in the Women's Circle of Health Study. *Cancer Causes Control*. 2014; 25:259–65. [PubMed: 24249438]
55. Martinez ME, Wertheim BC, Natarajan L, Schwab R, Bondy M, Daneri-Navarro A, Meza-Montenegro MM, Gutierrez-Milan LE, Brewster A, Komenaka IK, Thompson PA. Reproductive factors, heterogeneity, and breast tumor subtypes in women of Mexican descent. *Cancer Epidemiol Biomarkers Prev*. 2013; 22:1853–1861. [PubMed: 23950213]
56. Clavel-Chapelon F, E3N Group. Cumulative number of menstrual cycles and breast cancer risk: Results from the E3N cohort study of French women. *Cancer Causes Control*. 2002; 13:831–838. [PubMed: 12462548]
57. Gray RH, Campbell OM, Apelo R, Eslami SS, Zacur H, Ramos RM, Gehret JC, Labbok MH. Risk of ovulation during lactation. *Lancet*. 1990; 335:25–29. [PubMed: 1967336]
58. Russo J, Mailo D, Hu YF, Balogh G, Sheriff F, Russo IH. Breast differentiation and its implication in cancer prevention. *Clin Cancer Res*. 2005; 11:931s–6s. [PubMed: 15701889]
59. Gustafsson L, Hallgren O, Mossberg AK, Pettersson J, Fischer W, Aronsson A, Svanborg C. HAMLET kills tumor cells by apoptosis: Structure, cellular mechanisms, and therapy. *J Nutr*. 2005; 135:1299–1303. [PubMed: 15867328]
60. Do Carmo Franca-Botelho A, Ferreira MC, Franca JL, Franca EL, Honorio-Franca AC. Breastfeeding and its relationship with reduction of breast cancer: A review. *Asian Pac J Cancer Prev*. 2012; 13:5327–5332. [PubMed: 23317179]
61. Lyons TR, Schedin PJ, Borges VF. Pregnancy and breast cancer: When they collide. *J Mammary Gland Biol Neoplasia*. 2009; 14:87–98. [PubMed: 19381788]
62. Amend K, Hicks D, Ambrosone CB. Breast cancer in African-American women: Differences in tumor biology from European-American women. *Cancer Res*. 2006; 66:8327–8330. [PubMed: 16951137]
63. Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. *J Natl Cancer Inst*. 2009; 101:984–992. [PubMed: 19584328]
64. Menashe I, Anderson WF, Jatoti I, Rosenberg PS. Underlying causes of the black-white racial disparity in breast cancer mortality: A population-based analysis. *J Natl Cancer Inst*. 2009; 101:993–1000. [PubMed: 19584327]
65. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW. The epidemiology of triple-negative breast cancer, including race. *Cancer Causes Control*. 2009; 20:1071–1082. [PubMed: 19343511]

66. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, Falusi A, Perou CM, Olopade OI. Population differences in breast cancer: Survey in indigenous African women reveals over-representation of triple-negative breast cancer. *J Clin Oncol*. 2009; 27:4515–4521. [PubMed: 19704069]

Table 1

Characteristics of breast cancer cases and controls in the WCHS, (n=2,451)

Characteristics	Controls N=1,620 N (%)	Pure IDC N=181 (21.8%) N (%)	Unadjusted OR (95% CI) for developing pure IDC	Mixed IDC/DCIS N=650 (78.2%) N (%)	Unadjusted OR (95% CI) for developing mixed IDC/DCIS	Unadjusted case- case OR (95% CI) for developing pure IDC vs mixed IDC/DCIS
Age (mean, SD)	49.7 (9.4)	50.6 (9.9)		51.3 (10.5) ^b		
Menopausal status (N, %)						
Pre	867 (53.5)	101 (55.8)	1.00	338 (52.0)	1.00	1.00
Post	753 (46.5)	80 (44.2)	0.91 (0.67, 1.24)	312 (48.0)	1.06 (0.89, 1.27)	0.86 (0.62, 1.20)
Race (N, %)						
AA	905 (55.9)	114 (63.0)	1.00	348 (53.5)	1.00	1.00 ^c
EA	715 (44.1)	67 (37.0)	0.75 (0.54, 1.02)	302 (46.5)	1.10 (0.92, 1.32)	0.68 (0.48, 0.95)
Education (N, %)						
High school	432 (26.7)	78 (43.1)	1.00 ^a	211 (32.5)	1.00 ^b	1.00 ^c
Some college	394 (24.3)	43 (23.8)	0.61 (0.41, 0.90)	154 (23.7)	0.80 (0.63, 1.03)	0.76 (0.49, 1.16)
College graduate	794 (49.0)	60 (33.1)	0.42 (0.29, 0.60)	285 (43.8)	0.74 (0.59, 0.91)	0.57 (0.39, 0.83)
Birthplace (N, %)						
US born	1,352 (83.5)	130 (71.8)	1.00 ^a	497 (76.7)	1.00 ^b	1.00
Caribbean	133 (8.2)	33 (18.2)	2.58 (1.69, 2.34)	86 (13.3)	1.75 (1.31, 2.34)	1.47 (0.94, 2.30)
Other	135 (8.3)	18 (9.9)	1.39 (0.82, 2.34)	65 (10.0)	1.30 (0.95, 1.78)	1.06 (0.61, 1.86)
Composite screening score (N, %)						
0+1	110 (6.8)	25 (13.8)	1.00 ^a	60 (9.2)	1.00	1.00
2	535 (33.0)	56 (30.9)	0.46 (0.28, 0.77)	194 (29.9)	0.67 (0.47, 0.95)	0.69 (0.40, 1.20)
3	975 (60.2)	100 (55.3)	0.45 (0.28, 0.73)	395 (60.9)	0.74 (0.53, 1.04)	0.61 (0.36, 1.02)

Abbreviations: WCHS, Women's Circle of Health Study; IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; OR, Odds ratio; CI, confidence intervals; SD, standard deviation; AA, African American; EA, European American P-values from Student's t-test for continuous variables, and from Chi-squared tests for categorical variables

^aP 0.05 for comparison of pure IDC versus controls

^bP 0.05 for comparison of mixed IDC versus controls

^cP 0.05 for comparison of pure IDC vs versus mixed IDC/DCIS

Table 2

Associations between breast cancer risk factors and pure IDC and mixed IDC/DCIS in the WCHS (n=2,451)

	Controls	Pure IDC/DCIS	OR (95% CI) ^a	Mixed IDC/DCIS	OR (95% CI) ^a
	N=1,620 N (%)	N=181 N (%)		N=650 N (%)	
Family history					
No	1,395 (86.2)	147 (81.2)	1.00	526 (80.9)	1.00
Yes	224 (13.8)	34 (18.8)	1.54 (1.02, 2.34)	124 (19.1)	1.44 (1.12, 1.85)
			P=0.04		P=0.004
Age at menarche (yrs)					
14	420 (26.0)	45 (24.9)	1.00	180 (28.0)	1.00
12 to 13	784 (48.7)	80 (44.2)	1.03 (0.70, 1.53)	316 (49.2)	1.12 (0.89, 1.42)
<12	407 (25.3)	56 (30.9)	1.39 (0.90, 2.13)	146 (22.8)	1.23 (0.95, 1.60)
			P-trend=0.13		P-trend=0.12
OC use (mos)					
0	604 (37.3)	74 (40.9)	1.00	242 (37.3)	1.00
1 to 72	608 (37.6)	58 (32.0)	1.00 (0.69, 1.46)	232 (35.7)	1.12 (0.89, 1.40)
>72	407 (25.1)	49 (27.0)	1.36 (0.91, 2.05)	175 (27.0)	1.30 (1.02, 1.66)
			P-trend=0.16		P-trend=0.03
Postmenopausal MHT use					
No	516 (68.5)	51 (63.8)	1.00	212 (67.9)	1.00
Yes	237 (31.5)	29 (36.2)	1.37 (0.80, 2.35)	100 (32.1)	0.99 (0.73, 1.35)
			P=0.25		P=0.94
Current BMI (kg/m ²), <i>Premenopausal</i>					
<25	297 (34.6)	31 (31.0)	1.00	115 (34.8)	1.00
25 to <30	231 (26.9)	24 (24.0)	0.77 (0.43, 1.39)	100 (30.3)	1.12 (0.80, 1.57)
30	331 (38.5)	45 (45.0)	0.99 (0.58, 1.69)	115 (34.8)	0.90 (0.64, 1.27)
			P-trend=0.68		P-trend=0.77
Current BMI (kg/m ²), <i>Postmenopausal</i>					
<25	184 (25.0)	27 (36.5)	1.00	71 (23.3)	1.00
25 to <30	216 (29.3)	23 (31.1)	0.66 (0.35, 1.23)	86 (28.2)	1.08 (0.73, 1.60)
30	337 (45.7)	24 (32.4)	0.35 (0.18, 0.67)	148 (48.5)	1.08 (0.75, 1.57)
			P-trend=0.02		P-trend=0.58
Smoking					
No	909 (56.1)	113 (62.4)	1.00	365 (56.1)	1.00
Current/Former	711 (43.9)	68 (37.6)	0.76 (0.54, 1.07)	285 (43.9)	1.01 (0.83, 1.23)
			P=0.11		P=0.91
Parity					
0	348 (21.6)	38 (21.0)	1.00	150 (23.4)	1.00
1	343 (21.3)	31 (17.1)	0.70 (0.42, 1.17)	132 (20.6)	0.86 (0.64, 1.14)
2	469 (29.1)	60 (33.2)	0.98 (0.63, 1.52)	185 (28.9)	0.83 (0.64, 1.08)
3	450 (28.0)	52 (28.7)	0.67 (0.41, 1.07)	174 (27.2)	0.72 (0.55, 0.96)

	Controls	Pure IDC/DCIS	OR (95% CI) ^a	Mixed IDC/DCIS	OR (95% CI) ^a
	N=1,620 N (%)	N=181 N (%)		N=650 N (%)	
			P-trend=0.25		P-trend=0.03
Age at first birth (yrs) ^b					
22	558 (44.0)	68 (47.5)	1.00	225 (45.2)	1.00
>22 to 30	409 (32.3)	54 (37.8)	1.58 (1.02, 2.44)	175 (35.1)	1.14 (0.87, 1.50)
>30	301 (23.7)	21 (14.7)	0.93 (0.52, 1.65)	98 (19.7)	0.92 (0.66, 1.28)
			P-trend=0.84		P-trend=0.66
Age at last birth (yrs) ^c					
28	454 (35.8)	66 (46.1)	1.00	189 (38.0)	1.00
>28 to 33	356 (28.1)	41 (28.7)	0.89 (0.57, 1.37)	146 (29.3)	0.98 (0.74, 1.28)
>33	458 (36.1)	36 (25.2)	0.59 (0.37, 0.93)	163 (32.7)	0.85 (0.65, 1.10)
			P-trend=0.04		P-trend=0.15
Breastfeeding (mos) ^c					
None	547 (43.1)	75 (52.4)	1.00	213 (42.7)	1.00
>0-12	402 (31.6)	40 (28.0)	0.76 (0.49, 1.19)	171 (34.3)	1.15 (0.88, 1.50)
>12	321 (25.3)	28 (19.6)	0.61 (0.37, 1.02)	115 (23.0)	0.94 (0.70, 1.27)
			P-trend=0.07		P-trend=0.49

Abbreviations: IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; WCHS, Women's Circle of Health Study; OR, Odds Ratio; CI, confidence interval; AA, African American; EA, European American; OC, oral contraceptive; MHT, menstrual hormone therapy; BMI, body mass index

^aUnconditional logistic regression models were used to estimate ORs and 95% CIs. All models were adjusted for age, race, birthplace, family history, composite screening score, education, OC use, age at menarche, parity and menopausal status. All associations were adjusted for covariates listed above unless the covariate was the main exposure of interest or was used as a stratification variable (menopausal status for BMI and MHT use).

^bAmong 1,912 parous women only

^cAmong 1,912 parous women only, with an additional adjustment for age at first birth

Table 3

Case-case comparison of risk factors for pure IDC vs mixed IDC/DCIS in the WCHS (n=831)

	Pure IDC	Mixed IDC/DCIS	Model 1 Age-adjusted OR (95% CI) ^a	Model 2 Fully adjusted OR (95% CI) ^a	Model 3 Fully adjusted OR (95% CI) ^a
	N=181 N (%)	N=650 N (%)			
Race					
AA	114 (63.0)	348 (53.5)	1.00	1.00	1.00
EA	67 (37.0)	302 (46.5)	0.72 (0.52, 1.01)	0.82 (0.55, 1.20)	1.07 (0.67, 1.72)
			P=0.05	P=0.30	P=0.78
Family history					
No	147 (81.2)	526 (80.9)	1.00	1.00	1.00
Yes	34 (18.8)	124 (19.1)	0.99 (0.65, 1.51)	1.04 (0.67, 1.60)	1.07 (0.67, 1.72)
			P=0.70	P=0.87	P=0.78
Age at menarche (yrs)					
14	56 (30.9)	180 (28.0)	1.00	1.00	1.00
12 to 13	80 (44.2)	316 (49.2)	0.82 (0.54, 1.24)	0.90 (0.59, 1.38)	0.92 (0.57, 1.47)
<12	45 (24.9)	146 (22.7)	1.01 (0.64, 1.58)	1.06 (0.67, 1.67)	1.18 (0.71, 1.97)
			P-trend=0.90	P-trend=0.77	P-trend=0.46
OC use (mos)					
0	74 (40.9)	242 (37.3)	1.00	1.00	1.00
1 to 72	58 (32.0)	232 (35.8)	0.79 (0.54, 1.18)	0.86 (0.58, 1.29)	0.89 (0.57, 1.37)
>72	49 (27.1)	175 (27.0)	0.87 (0.57, 1.33)	0.98 (0.63, 1.51)	0.88 (0.54, 1.43)
			P-trend=0.46	P-trend=0.58	P-trend=0.88
Postmenopausal MHT use					
No	51 (63.8)	212 (68.0)	1.00	1.00	1.00
Yes	29 (36.3)	100 (32.1)	1.21 (0.72, 2.03)	1.38 (0.80, 2.38)	1.41 (0.78, 2.56)
			P=0.64	P=0.25	P=0.26
Current BMI (kg/m ²), <i>Premenopausal</i>					
<25	31 (31.0)	115 (34.9)	1.00	1.00	1.00
25 to <30	24 (24.0)	100 (30.3)	0.89 (0.49, 1.62)	0.73 (0.39, 1.37)	0.59 (0.29, 1.20)
30	45 (45.0)	115 (34.9)	1.45 (0.85, 2.46)	1.01 (0.54, 1.89)	0.89 (0.45, 1.78)
			P-trend=0.10	P-trend=0.76	P-trend=0.58
Current BMI (kg/m ²), <i>Postmenopausal</i>					
<25	27 (36.5)	71 (23.3)	1.00	1.00	1.00
25 to <30	23 (31.1)	86 (28.2)	0.70 (0.37, 1.33)	0.65 (0.33, 1.27)	0.73 (0.35, 1.51)
30	24 (32.4)	148 (48.5)	0.42 (0.23, 0.79)	0.36 (0.19, 0.70)	0.38 (0.19, 0.79)
			P-trend=0.03	P-trend=0.003	P-trend=0.01
Smoking					
No	113 (62.4)	365 (53.2)	1.00	1.00	1.00
Current/Former	68 (37.6)	285 (43.9)	0.78 (0.56, 1.10)	0.77 (0.53, 1.11)	0.68 (0.45, 1.01)
			P=0.16	P=0.15	P=0.06
Parity					

	Pure IDC N=181 N (%)	Mixed IDC/DCIS N=650 N (%)	Model 1 Age-adjusted OR (95% CI) ^a	Model 2 Fully adjusted OR (95% CI) ^a	Model 3 Fully adjusted OR (95% CI) ^a
0	38 (21.0)	151 (23.2)	1.00	1.00	1.00
1	31 (17.1)	133 (20.5)	0.93 (0.55, 1.57)	0.82 (0.48, 1.40)	0.80 (0.43, 1.46)
2	60 (33.2)	190 (29.2)	1.27 (0.80, 2.01)	1.17 (0.73, 1.88)	1.11 (0.66, 1.87)
3	52 (28.7)	176 (27.1)	1.21 (0.75, 1.94)	0.92 (0.56, 1.53)	0.74 (0.42, 1.31)
			P-trend=0.26	P-trend=0.88	P-trend=0.56
Age at first birth (yrs) ^b					
22	68 (47.5)	225 (45.2)	1.00	1.00	1.00
>22 to 30	54 (37.8)	175 (35.1)	1.01 (0.67, 1.53)	1.37 (0.86, 2.16)	1.43 (0.86, 2.36)
>30	21 (14.7)	98 (19.7)	0.69 (0.40, 1.19)	1.11 (0.59, 2.08)	1.33 (0.65, 2.70)
			P-trend=0.23	P-trend=0.56	P-trend=0.66
Age at last birth (yrs) ^c					
28	66 (46.1)	189 (38.0)	1.00	1.00	1.00
>28 to 33	41 (28.7)	146 (29.3)	0.80 (0.51, 1.24)	0.81 (0.49, 1.32)	0.77 (0.45, 1.31)
>33	36 (25.2)	163 (32.7)	0.63 (0.40, 1.00)	0.63 (0.36, 1.10)	0.75 (0.44, 1.27)
			P-trend=0.04	P-trend=0.10	P-trend=0.28
Breastfeeding (mos) ^c					
None	75 (52.4)	213 (42.7)	1.00	1.00	1.00
>0-12	40 (28.0)	171 (34.3)	0.63 (0.40, 0.97)	0.62 (0.39, 1.01)	0.55 (0.32, 0.94)
>12	28 (19.6)	115 (23.0)	0.64 (0.39, 1.05)	0.58 (0.34, 1.01)	0.47 (0.36, 0.87)
			P-trend=0.14	P-trend=0.11	P-trend=0.18

Abbreviations: IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; WCHS, Women's Circle of Health Study; OR, Odds Ratio; CI, confidence interval; AA, African American; EA, European American; OC, oral contraceptive; MHT, menstrual hormone therapy; BMI, body mass index

Model 1 was adjusted for age only.

Model 2 was adjusted for age, race, birthplace, family history, composite screening score, education, OC use, age at menarche, parity and menopausal status.

Model 3 was adjusted for all variables in Model 2 with the addition of ER status.

All associations were adjusted for covariates listed above unless the covariate was the main exposure of interest or was used as a stratification variable (menopausal status for BMI and MHT use).

^aUnconditional logistic regression models were used to estimate ORs and 95% CIs.

^bAmong 642 parous women only

^cAmong 642 parous women only, with an additional adjustment for age at first birth

Table 4

Associations between breast cancer risk factors and odds of pure IDC compared to mixed IDC/DCIS, by AA and EA race, in the Women's Circle of Health Study, (N=755)

	AA			EA		
	Pure IDC N=108 N (%)	Mixed IDC/DCIS N=317 N (%)	OR (95% CI) ^a	Pure IDC N=67 N (%)	Mixed IDC/DCIS N=263 N (%)	OR (95% CI) ^a
Age (yrs)						
<45	35 (32.4)	97 (30.6)	0.88 (0.47, 1.67)	17 (25.4)	67 (25.5)	0.93 (0.43, 2.03)
45	73 (67.6)	220 (69.4)	1.00	50 (74.6)	196 (74.5)	1.00
			P=0.70			P=0.86
Family history						
No	94 (87.0)	271 (85.5)	1.00	48 (71.6)	198 (75.3)	1.00
Yes	14 (13.0)	46 (14.5)	0.84 (0.42, 1.67)	19 (28.4)	65 (24.7)	1.17 (0.62, 2.21)
			P=0.62			P=0.63
Age at menarche (yrs)						
14	27 (25.0)	83 (26.2)	1.00	11 (16.4)	49 (18.6)	1.00
12 to 13	50 (46.3)	141 (44.5)	1.13 (0.63, 2.02)	32 (47.8)	146 (55.5)	0.84 (0.38, 1.83)
<12	31 (28.7)	93 (29.3)	1.15 (0.61, 2.17)	24 (35.8)	68 (25.9)	1.41 (0.62, 3.22)
			P-trend=0.68			P-trend=0.28
OC use (mos)						
0	44 (40.7)	123 (38.9)	1.00	28 (47.8)	91 (34.6)	1.00
1 to 72	37 (34.3)	113 (35.8)	0.97 (0.56, 1.67)	24 (35.8)	94 (35.7)	0.83 (0.43, 1.63)
>72	27 (25.0)	80 (25.3)	0.98 (0.54, 1.81)	15 (22.4)	78 (29.7)	0.68 (0.31, 1.48)
			P-trend=0.62			P-trend=0.41
Postmenopausal MHT use						
No	33 (68.7)	121 (74.2)	1.00	16 (50.0)	72 (60.5)	1.00
Yes	15 (31.3)	42 (25.8)	1.26 (0.58, 2.74)	16 (50.0)	47 (39.5)	2.06 (0.80, 5.30)
			P=0.56			P=0.14
Current BMI (kg/m ²), Premenopausal						
25	13 (21.7)	30 (19.7)	1.00	16 (47.1)	71 (50.7)	1.00
>25 to 30	14 (23.3)	48 (31.6)	0.46 (0.17, 1.23)	6 (17.6)	41 (29.3)	0.52 (0.17, 1.60)
>30	33 (55.0)	74 (48.7)	0.64 (0.26, 1.57)	12 (35.3)	28 (20.0)	1.88 (0.64, 5.53)
			P-trend=0.89			P-trend=0.68
Current BMI (kg/m ²), Postmenopausal						
25	12 (26.7)	23 (14.5)	1.00	12 (38.7)	42 (36.2)	1.00
>25 to 30	16 (35.5)	43 (27.0)	0.62 (0.23, 1.69)	9 (29.0)	32 (27.6)	1.02 (0.33, 3.15)
>30	17 (37.8)	93 (58.5)	0.33 (0.13, 0.86)	10 (32.3)	42 (36.2)	0.70 (0.23, 2.15)
			P-trend=0.03			P-trend=0.53
Smoking						
No	72 (66.7)	193 (60.9)	1.00	36 (53.7)	137 (52.1)	1.00
Current/Former	36 (33.3)	124 (39.1)	0.71 (0.41, 1.21)	31 (46.3)	126 (47.9)	0.95 (0.54, 1.70)

	AA			EA		
	Pure IDC	Mixed IDC/DCIS	OR (95% CI) ^a	Pure IDC	Mixed IDC/DCIS	OR (95% CI) ^a
	N=108 N (%)	N=317 N (%)		N=67 N (%)	N=263 N (%)	
			P=0.21			P=0.87
Parity						
0	14 (12.3)	54 (15.5)	1.00	24 (35.8)	97 (32.1)	1.00
1	22 (19.3)	85 (26.6)	0.78 (0.33, 1.84)	9 (13.4)	48 (15.9)	0.80 (0.30, 2.11)
2	38 (33.3)	93 (26.7)	1.14 (0.52, 2.51)	22 (32.8)	97 (32.1)	1.06 (0.51, 2.21)
3	40 (35.1)	116 (33.3)	0.79 (0.35, 1.78)	12 (17.9)	60 (19.9)	0.65 (0.56, 1.65)
			P-trend=0.79			P-trend=0.58
Age at first birth (yrs) ^b						
22	54 (58.7)	168 (62.9)	1.00	10 (23.8)	38 (21.4)	1.00
>22 to 30	29 (31.5)	73 (27.3)	1.30 (0.72, 2.40)	20 (47.6)	83 (46.6)	0.81 (0.30, 2.16)
>30	9 (9.78)	26 (9.7)	1.79 (0.72, 4.45)	12 (28.6)	57 (32.0)	0.76 (0.23, 2.49)
			P-trend=0.67			P-trend=0.92
Age at last birth (yrs) ^c						
28	52 (56.5)	131 (49.1)	1.00	11 (26.2)	42 (23.6)	1.00
>28 to 33	20 (21.7)	63 (23.6)	0.70 (0.36, 1.36)	15 (35.7)	66 (37.1)	0.82 (0.31, 2.16)
>33	20 (21.7)	73 (27.3)	0.75 (0.40, 1.42)	16 (38.1)	70 (39.3)	0.81 (0.31, 2.11)
			P-trend=0.19			P-trend=0.88
Breastfeeding (months) ^c						
None	52 (56.5)	132 (49.3)	1.00	23 (54.8)	61 (34.3)	1.00
>0-12	25 (27.2)	78 (29.1)	0.69 (0.36, 1.33)	11 (26.2)	70 (39.3)	0.34 (0.14, 0.84)
>12	15 (16.3)	58 (21.6)	0.47 (0.22, 1.04)	8 (19.0)	47 (26.4)	0.37 (0.14, 1.03)
			P-trend=0.20			P-trend=0.25

Abbreviations: IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; ER, estrogen receptor; OR, Odds Ratio; CI, confidence interval; AA, African American; EA, European American; MHT, menstrual hormone therapy; BMI, body mass index

^aUnconditional logistic regression was used to estimate odds of having pure IDC versus mixed IDC/DCIS, with analyses adjusted for age, birthplace, family history, composite screening score, education, OC use, age at menarche, parity, menopausal status and ER status. Analysis of MHT use was not adjusted for menopausal status since only postmenopausal women were included in the analysis. Associations were adjusted for covariates listed above unless the covariate was the main exposure of interest or was used as a stratification variable.

^bAmong 580 parous women only.

^cAmong 580 women only, with an additional adjustment for age at first birth.

Table 5

Associations between tumor characteristics and odds of pure IDC compared to mixed IDC/DCIS in the Women's Circle of Health Study (n=755)

	Pure IDC N=175 N (%)	Mixed IDC/DCIS N=580 N (%)	OR (95% CI) ^a
Age (yrs)			
<45	52 (29.7)	164 (28.3)	1.00
45	123 (70.3)	416 (71.7)	1.17 (0.65, 2.11)
			P=0.61
Tumor size (cm)			
<2	74 (49.7)	347 (63.7)	1.00
2-<5	63 (42.3)	174 (31.9)	1.58 (1.07, 2.35)
5	12 (8.0)	24 (4.4)	2.16 (1.00, 4.67)
			P-trend=0.008
Tumor grade			
1	22 (13.6)	91 (16.2)	1.00
2	48 (29.6)	240 (42.7)	0.75 (0.43, 1.34)
3	92 (56.8)	231(41.1)	1.49 (0.86, 2.57)
			P-trend=0.01
TNM stage			
1	45 (38.8)	233 (49.8)	1.00
2	58 (50.0)	169 (36.1)	1.63 (1.03, 2.57)
3	13 (11.2)	66 (14.1)	0.87 (0.43, 1.75)
			P-trend=0.63
Lymph nodes			
Negative	81 (68.1)	269 (58.2)	1.00
Positive	38 (31.9)	193 (41.8)	0.55 (0.35, 0.87)
			P=0.01
Lymphovascular invasion			
Negative	92 (73.6)	281 (64.3)	1.00
Positive	33 (26.4)	156 (35.7)	0.58 (0.36, 0.92)
			P=0.02
ER			
Positive	96 (54.9)	450 (77.6)	1.00
Negative	79 (45.1)	130 (22.4)	2.79 (1.93, 4.05)
			P<0.0001
PR			
Positive	88 (50.9)	370 (66.3)	1.00
Negative	85 (49.1)	188 (33.7)	1.87 (1.30, 2.68)
			P=0.0008
HER2			
Negative	136 (84.0)	415 (77.9)	1.00

	Pure IDC N=175 N (%)	Mixed IDC/DCIS N=580 N (%)	OR (95% CI) ^a
Positive	26 (16.0)	118 (22.1)	0.65 (0.41, 1.05)
			P=0.08
Breast cancer subtypes			
Luminal A	79 (49.1)	341 (64.2)	1.00
Luminal B	14 (8.70)	78 (14.7)	0.78 (0.41, 1.46)
Nonluminal	12 (7.45)	40 (7.53)	1.30 (0.64, 2.63)
Triple negative	56 (34.8)	72 (13.6)	3.26 (2.08, 5.12)
			P<0.0001
Method of tumor discovery			
Mammogram	53 (32.5)	231 (43.7)	1.00
Palpation	110 (67.5)	298 (56.3)	1.54 (1.02, 2.32)
			P=0.04

Abbreviations: IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; OR, Odds Ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2, OC, oral contraceptive

^aUnconditional logistic regression models were used to estimate ORs and 95% CIs. All models were adjusted for age, race, birthplace, family history, composite screening score, education, OC use, age at menarche, parity and menopausal status. Associations were adjusted for covariates listed above unless the covariate was the main exposure of interest.